CY1115188T1 - Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl - Google Patents
Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axlInfo
- Publication number
- CY1115188T1 CY1115188T1 CY20141100312T CY141100312T CY1115188T1 CY 1115188 T1 CY1115188 T1 CY 1115188T1 CY 20141100312 T CY20141100312 T CY 20141100312T CY 141100312 T CY141100312 T CY 141100312T CY 1115188 T1 CY1115188 T1 CY 1115188T1
- Authority
- CY
- Cyprus
- Prior art keywords
- axl
- polycyclic heteroaryl
- suspensions
- substituted triazoles
- triazoles useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Virology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Αποκαλύπτονται πολυκυκλικές ετεραρυλ-υποκατεστημένες τριαζόλες και φαρμακευτικές συνθέσεις που περιέχουν τις ενώσεις, οι οποίες είναι χρήσιμες στην αναστολή της ενεργότητας του υποδοχέα πρωτεϊνικής κινάσης τυροσίνης Axl. Αποκαλύπτονται επίσης μέθοδοι για χρήση των ενώσεων στη θεραπεία ασθενειών και καταστάσεων που σχετίζονται με την ενεργότητα του Axl.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88285006P | 2006-12-29 | 2006-12-29 | |
US89540007P | 2007-03-16 | 2007-03-16 | |
US97093107P | 2007-09-07 | 2007-09-07 | |
EP07870107.5A EP2078010B1 (en) | 2006-12-29 | 2007-12-29 | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115188T1 true CY1115188T1 (el) | 2017-01-04 |
Family
ID=39387343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100312T CY1115188T1 (el) | 2006-12-29 | 2014-04-28 | Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl |
Country Status (17)
Country | Link |
---|---|
US (5) | US7709482B2 (el) |
EP (1) | EP2078010B1 (el) |
JP (2) | JP5546250B2 (el) |
CN (1) | CN101622246B (el) |
AU (1) | AU2007341937B2 (el) |
CA (1) | CA2710234C (el) |
CY (1) | CY1115188T1 (el) |
DK (1) | DK2078010T3 (el) |
ES (1) | ES2460894T3 (el) |
HK (1) | HK1132737A1 (el) |
HR (1) | HRP20140378T1 (el) |
ME (1) | ME01832B (el) |
PL (1) | PL2078010T3 (el) |
PT (1) | PT2078010E (el) |
RS (1) | RS53281B (el) |
SI (1) | SI2078010T1 (el) |
WO (1) | WO2008083367A2 (el) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2612788A1 (en) * | 2005-06-24 | 2006-12-28 | Steven Cesar Alfons De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c |
WO2007030680A2 (en) * | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
US8338435B2 (en) * | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
TW200840584A (en) * | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
RS53281B (en) | 2006-12-29 | 2014-08-29 | Rigel Pharmaceuticals Inc. | POLYCYCLIC HETEROaryl SUBSTITUTED TRIAZOLES USED AS AXL INHIBITORS |
PL2114955T3 (pl) * | 2006-12-29 | 2013-06-28 | Rigel Pharmaceuticals Inc | Triazole podstawione mostkowanym bicyklicznym arylem oraz mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory Axl |
JP5567837B2 (ja) * | 2006-12-29 | 2014-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール |
ES2406930T3 (es) * | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
CA2946305C (en) | 2006-12-29 | 2019-09-17 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
US7935693B2 (en) * | 2007-10-26 | 2011-05-03 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as Axl inhibitors |
NZ587589A (en) | 2008-02-15 | 2012-10-26 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
ES2537480T3 (es) | 2008-07-09 | 2015-06-08 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl |
ES2399319T3 (es) | 2008-07-09 | 2013-03-27 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con heteroarilos bicíclicos que contienen puentes útiles como inhibidores de AXL |
JP4644273B2 (ja) * | 2008-07-15 | 2011-03-02 | 本田技研工業株式会社 | 車両周辺監視装置 |
US8546433B2 (en) * | 2009-01-16 | 2013-10-01 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
AU2011207381B2 (en) | 2010-01-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
US9074192B2 (en) | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
PT2810937T (pt) | 2012-01-31 | 2017-03-03 | Daiichi Sankyo Co Ltd | Derivado de piridona |
EP3184121A3 (en) | 2012-07-25 | 2017-09-27 | Salk Institute For Biological Studies | Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases |
TW201534597A (zh) * | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
EP3071204B1 (en) | 2013-11-20 | 2019-02-20 | SignalChem Lifesciences Corp. | Quinazoline derivatives as tam family kinase inhibitors |
CN110156770B (zh) | 2013-11-27 | 2022-10-04 | 圣诺康生命科学公司 | 作为tam族激酶抑制剂的氨基吡啶衍生物 |
US9801880B2 (en) | 2013-12-02 | 2017-10-31 | Bergenbio As | Use of kinase inhibitors |
TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
CA2909669C (en) | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
GB201420285D0 (en) * | 2014-11-14 | 2014-12-31 | Bergenbio As | Process |
WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
ES2896079T3 (es) | 2016-02-26 | 2022-02-23 | Ono Pharmaceutical Co | Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario |
PT3436461T (pt) | 2016-03-28 | 2024-01-23 | Incyte Corp | Compostos de pirrolotriazina como inibidores de tam |
CN106083764B (zh) * | 2016-07-11 | 2018-09-18 | 上海皓元生物医药科技有限公司 | 一种用于制备axl抑制剂的高纯度中间体的手性拆分方法 |
JP7156287B2 (ja) | 2017-08-23 | 2022-10-19 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含むがん治療剤 |
JP2020535168A (ja) | 2017-09-27 | 2020-12-03 | インサイト・コーポレイションIncyte Corporation | Tam阻害剤として有用なピロロトリアジン誘導体の塩 |
WO2019074116A1 (ja) | 2017-10-13 | 2019-04-18 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
TWI832871B (zh) | 2018-06-29 | 2024-02-21 | 美商英塞特公司 | Axl/mer 抑制劑之調配物 |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
KR20230013241A (ko) | 2020-04-08 | 2023-01-26 | 베르겐바이오 에이에스에이 | 항바이러스 요법을 위한 axl 억제제 |
GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
TW202304908A (zh) * | 2021-04-14 | 2023-02-01 | 日商衛材R&D企管股份有限公司 | 四氫吡啶并嘧啶化合物 |
CN115504967A (zh) * | 2021-06-23 | 2022-12-23 | 南京正大天晴制药有限公司 | 作为axl抑制剂的1,2,4-***化合物 |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
GB202209285D0 (en) | 2022-06-24 | 2022-08-10 | Bergenbio Asa | Dosage regimen for AXL inhibitor |
WO2024051667A1 (zh) * | 2022-09-05 | 2024-03-14 | 南京正大天晴制药有限公司 | 具有axl抑制活性的取代***化合物 |
WO2024054793A1 (en) * | 2022-09-09 | 2024-03-14 | University Of Rochester | Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1403866A (en) * | 1971-12-06 | 1975-08-28 | Wyeth John & Brother Ltd | Derivatives of 3-amino-1,2,4-triazoles |
WO1995003286A1 (fr) | 1993-07-23 | 1995-02-02 | The Green Cross Corporation | Derive de triazole et son utilisation pharmaceutique |
GB9918180D0 (en) | 1999-08-02 | 1999-10-06 | Smithkline Beecham Plc | Novel compositions |
CA2432870A1 (en) * | 2000-12-22 | 2002-07-25 | Ronghui Lin | Substituted triazole diamine derivatives as kinase inhibitors |
TW201041580A (en) | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
EP1504047B1 (en) | 2002-05-03 | 2007-12-12 | Janssen Pharmaceutica N.V. | Polymeric microemulsions |
WO2004017997A1 (ja) | 2002-08-06 | 2004-03-04 | Toray Industries, Inc. | 腎疾患治療又は予防剤及び腎疾患の診断方法 |
EP1563094A4 (en) * | 2002-10-29 | 2007-04-25 | Rigel Pharmaceuticals Inc | MODULATORS OF ANGIOGENESIS AND TUMORIGENESIS |
CN1738615A (zh) * | 2002-11-15 | 2006-02-22 | 沃泰克斯药物股份有限公司 | 用作蛋白质激酶的抑制剂的二氨基***类 |
CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
JP4889489B2 (ja) | 2003-08-06 | 2012-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なアミノトリアゾール化合物 |
JP2007522213A (ja) | 2004-02-11 | 2007-08-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換されたトリアゾール化合物の製造方法 |
GB2415863A (en) | 2004-07-01 | 2006-01-04 | British Sky Broadcasting Ltd | Wireless network system and devices with redundancy between orthogonally polarised beams |
KR20070049655A (ko) * | 2004-08-13 | 2007-05-11 | 제넨테크, 인크. | Atp-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도 |
ZA200702645B (en) * | 2004-09-17 | 2008-08-27 | Vertex Pharma | Diaminotriazole compounds useful as protein kinase inhibitors |
US9265731B2 (en) * | 2005-01-28 | 2016-02-23 | Bend Research, Inc. | Drying of drug-containing particles |
WO2007030680A2 (en) * | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
WO2008045978A1 (en) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
FR2908131B1 (fr) | 2006-11-03 | 2009-01-09 | Univ Haute Alsace Etablissemen | Derives d'aminobenzocycloheptene,leurs procedes de preparation et leur utilisation en therapeutique |
US7879856B2 (en) | 2006-12-22 | 2011-02-01 | Rigel Pharmaceuticals, Inc. | Diaminothiazoles useful as Axl inhibitors |
JP5567837B2 (ja) | 2006-12-29 | 2014-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール |
ES2406930T3 (es) | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
CA2946305C (en) | 2006-12-29 | 2019-09-17 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
RS53281B (en) * | 2006-12-29 | 2014-08-29 | Rigel Pharmaceuticals Inc. | POLYCYCLIC HETEROaryl SUBSTITUTED TRIAZOLES USED AS AXL INHIBITORS |
PL2114955T3 (pl) * | 2006-12-29 | 2013-06-28 | Rigel Pharmaceuticals Inc | Triazole podstawione mostkowanym bicyklicznym arylem oraz mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory Axl |
EP2170867A1 (en) | 2007-06-15 | 2010-04-07 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
US7935693B2 (en) | 2007-10-26 | 2011-05-03 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as Axl inhibitors |
NZ587589A (en) | 2008-02-15 | 2012-10-26 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
ES2537480T3 (es) | 2008-07-09 | 2015-06-08 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl |
ES2399319T3 (es) | 2008-07-09 | 2013-03-27 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con heteroarilos bicíclicos que contienen puentes útiles como inhibidores de AXL |
US8546433B2 (en) | 2009-01-16 | 2013-10-01 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
CA2766735C (en) | 2011-02-07 | 2020-06-02 | Ortho-Clinical Diagnostics, Inc. | Determining conditions in centrifuged blood using measured pressure |
-
2007
- 2007-12-29 RS RS20140215A patent/RS53281B/en unknown
- 2007-12-29 AU AU2007341937A patent/AU2007341937B2/en active Active
- 2007-12-29 US US11/967,172 patent/US7709482B2/en active Active
- 2007-12-29 JP JP2009544316A patent/JP5546250B2/ja active Active
- 2007-12-29 PT PT78701075T patent/PT2078010E/pt unknown
- 2007-12-29 PL PL07870107T patent/PL2078010T3/pl unknown
- 2007-12-29 WO PCT/US2007/089177 patent/WO2008083367A2/en active Application Filing
- 2007-12-29 SI SI200731449T patent/SI2078010T1/sl unknown
- 2007-12-29 ES ES07870107.5T patent/ES2460894T3/es active Active
- 2007-12-29 DK DK07870107.5T patent/DK2078010T3/da active
- 2007-12-29 ME MEP-2014-47A patent/ME01832B/me unknown
- 2007-12-29 CA CA2710234A patent/CA2710234C/en active Active
- 2007-12-29 EP EP07870107.5A patent/EP2078010B1/en active Active
- 2007-12-29 CN CN200780048656.9A patent/CN101622246B/zh active Active
-
2009
- 2009-12-31 HK HK09112399.3A patent/HK1132737A1/xx unknown
-
2010
- 2010-03-09 US US12/720,448 patent/US8618331B2/en active Active
-
2011
- 2011-01-07 US US12/986,951 patent/US8168636B2/en active Active
-
2012
- 2012-03-19 US US13/423,924 patent/US8741898B2/en active Active
-
2014
- 2014-02-07 JP JP2014021926A patent/JP5797792B2/ja active Active
- 2014-04-24 US US14/261,094 patent/US9156820B2/en active Active
- 2014-04-24 HR HRP20140378TT patent/HRP20140378T1/hr unknown
- 2014-04-28 CY CY20141100312T patent/CY1115188T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115188T1 (el) | Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl | |
CY1113642T1 (el) | Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl | |
CY1121848T1 (el) | Διυποκατεστημενα οκταϋδροπυρρολο [3,4-c]πυρρολια ως ρυθμιστες υποδοχεα ορεξινης | |
CY1114148T1 (el) | Γεφυρωμενες δικυκλικες αρυλο- και γεφυρωμενες δικυκλικες etepoapyλo-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις toy axl | |
ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
CY1116809T1 (el) | 5-μελη ετεροκυκλικα αμιδια και σχετικες ενωσεις | |
CY1114277T1 (el) | ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ | |
CY1114539T1 (el) | Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων | |
DK1951729T3 (da) | Oxygenbundne pyrimidinderivater | |
BRPI0514537B8 (pt) | compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende | |
EA200970738A1 (ru) | Ингибиторы активности akt | |
EA200800555A1 (ru) | Производные ксантина в качестве селективных агонистов hm74a | |
ECSP088561A (es) | Derivados de pirimidinil-aril-urea que son inhibidores de fgf | |
EA200800441A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов киназ | |
BRPI0821151A2 (pt) | Derivados de pirazol e uso dos mesmos como inibidores de quinases dependentes de ciclina | |
CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
PL1877364T3 (pl) | Pochodne fenyloacetylenu o powinowactwie do receptora mGluR5 | |
MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
MX2010000098A (es) | Derivados de guanina policiclicos y sus metodos de uso. | |
CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
MY147649A (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
DE602006014305D1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
TW200745081A (en) | Compounds |